Cargando…

Vemurafenib- and Cobimetinib-Associated Drug Reaction With Eosinophilia and Systemic Symptoms in a Patient With Metastatic Melanoma

Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe hypersensitivity reaction associated with drug exposure. Recognizing signs of DRESS and stopping the offending agent is essential for proper treatment. In this case report, we present an interesting case of DRESS following the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Saedy, Miriam, Al-Saedy, Salsabeal, Rieck, Chad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Dermatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470976/ https://www.ncbi.nlm.nih.gov/pubmed/37664366 http://dx.doi.org/10.7759/cureus.44462

Ejemplares similares

Drug Reaction With Eosinophilia and Systemic Symptoms: A Diagnostic Dilemma
por: Vecin, Nicole M, et al.
Publicado: (2023)

Drug-Induced Reaction With Eosinophilia and Systemic Symptoms: A Review
por: Alotaibi, Moteb
Publicado: (2023)

A Comprehensive Analysis of Topiramate and Drug Reaction With Eosinophilia and Systemic Symptoms
por: Thoms, Amelia, et al.
Publicado: (2023)

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
por: Shaikh, Saba S., et al.
Publicado: (2022)

Drug Reaction With Eosinophilia and Systemic Symptom (DRESS) Following Rifampicin Treatment: A Case Report
por: Shrestha, Ramesh, et al.
Publicado: (2021)

Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Caused by Apalutamide: A Case Presentation
por: Martin, Gabriella, et al.
Publicado: (2023)

Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib
por: Gavric, Ana Ursula, et al.
Publicado: (2018)

Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
por: Álamo, Mª del Carmen, et al.
Publicado: (2021)

A Fatal Case of Vancomycin Associated Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome in a Septuagenarian
por: Gangireddy, Mounika, et al.
Publicado: (2019)

Non-aromatic Anticonvulsant (Divalproex Sodium)-Induced Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome
por: Dutta, Priyata, et al.
Publicado: (2021)

Drug Rash with Eosinophilia and Systemic Symptoms: Two Emergency Department Cases
por: Tsyrulnik, Alina, et al.
Publicado: (2011)

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
por: Piejko, Karolina, et al.
Publicado: (2023)

A Case of Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome in a Patient Receiving Peritoneal Dialysis With Icodextrin Exposure
por: Alotaibi, Manal E, et al.
Publicado: (2022)

Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma
por: Cai, Chao, et al.
Publicado: (2021)

Recurrent Leflunomide-Induced Drug Reaction With Eosinophilia and Systemic Symptom (DRESS) Syndrome Despite Prolonged Steroid Taper: A Case Report
por: Gayfield, Scott, et al.
Publicado: (2022)

Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients
por: Daud, Adil, et al.
Publicado: (2017)

A Case of Amoxicillin-Induced Drug Reaction With Eosinophilia and Systemic Symptoms (Dress) Syndrome Associated With Significant Reactive Hypereosinophilia (HE): A Case Report
por: Oh, Jaha, et al.
Publicado: (2023)

Stevens-Johnson Syndrome and Severe Anaemia: A Case of Toxicity Induced by Vemurafenib plus Cobimetinib following Pembrolizumab for Metastatic Melanoma
por: BATINAC, Tanja, et al.
Publicado: (2022)

COVID-19 Vaccine: A Common Suspect but Rare Culprit in Drug Rash With Eosinophilia and Systemic Symptoms (DRESS) Syndrome
por: Hanna, Mary, et al.
Publicado: (2022)

Adult Blaschkitis With Lichenoid Features and Blood Eosinophilia
por: Al-Balbeesi, Amal
Publicado: (2021)

The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib
por: Medina, Theresa M, et al.
Publicado: (2016)

Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF(V600) mutation–positive melanoma
por: Dréno, Brigitte, et al.
Publicado: (2018)

Cobimetinib- and vemurafenib-induced granulomatous dermatitis and erythema induratum: A case report
por: Iafolla, Marco AJ, et al.
Publicado: (2019)

Successful transition to encorafenib following vemurafenib-induced drug rash with eosinophilia and systemic symptoms syndrome
por: Young, Peter A., et al.
Publicado: (2021)

Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials
por: Hopkins, Ashley M., et al.
Publicado: (2020)

Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study
por: Kähler, Katharina C., et al.
Publicado: (2021)

Drug Rash with Eosinophilia and Systemic Symptoms Syndrome Presenting After the Initiation of Staphylococcus hominis Infectious Endocarditis Treatment: A Case Report and Updated Review of Management Considerations
por: Nguyen, Khoa, et al.
Publicado: (2018)

Successful use of dabrafenib after the occurrence of drug rash with eosinophilia and systemic symptoms (DRESS) induced by vemurafenib
por: Pinard, Camille, et al.
Publicado: (2017)

SK119, a Novel Shikonin Derivative, Leads to Apoptosis in Melanoma Cell Lines and Exhibits Synergistic Effects with Vemurafenib and Cobimetinib
por: Kretschmer, Nadine, et al.
Publicado: (2022)

Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials
por: Ascierto, Paolo A., et al.
Publicado: (2020)

Metastatic Malignant Melanoma With Occult Primary Presenting as Breast Mass: A Case Report and Literature Review
por: Harsten, Rebecca M, et al.
Publicado: (2021)

Metastatic melanoma and vemurafenib: novel approaches
por: De Mello, Ramon Andrade
Publicado: (2012)

Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma
por: de Haan, Jorine, et al.
Publicado: (2018)

Interstitial Granulomatous Drug Reaction: A Case Report
por: Aldibane, Raghad T, et al.
Publicado: (2022)

coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAF(V600) mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)
por: Ascierto, Paolo A, et al.
Publicado: (2015)

Refractory pityriasis rubra pilaris treated with upadacitinib
por: Song, Eingun James, et al.
Publicado: (2023)

Successful treatment of refractory subacute cutaneous lupus erythematosus with deucravacitinib
por: Bouché, Nicole, et al.
Publicado: (2023)

Tumoral Melanosis Associated with Pembrolizumab-Treated Metastatic Melanoma
por: Bari, Omar, et al.
Publicado: (2017)

Metastatic Melanoma: A Consequence of the COVID-19 Pandemic
por: Phillips, Robert L, et al.
Publicado: (2023)

Scleredema Adultorum of Buschke Associated With Diffuse Eosinophilia and Hepatitis B Virus Infection
por: Patel, Divya R, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_akve3lb150oipidtkgcunerd7o